CPC A61K 38/28 (2013.01) [A61K 31/437 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/529 (2013.01); A61K 31/5355 (2013.01); A61K 31/541 (2013.01); A61K 31/553 (2013.01); A61K 38/1709 (2013.01); A61K 38/465 (2013.01); A61K 38/51 (2013.01); A61P 3/10 (2018.01)] | 11 Claims |
1. A method of delaying the onset of type 1 diabetes (T1D) in an individual having or at risk of having T1D, the method comprising providing in the individual:
an anti-inflammatory compound; and
a pancreatic autoantigen or a derivative or variant thereof;
thereby delaying the onset of T1D in the individual;
wherein the anti-inflammatory compound is Ruxolitinib, and
wherein the pancreatic autoantigen is proinsulin or a derivative or variant thereof.
|